Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Akeladine versus sorafenib as first-line treatment for PD-L1-positive advanced hepatocellular carcinoma
CTR20170668Phase 3Active
- Sponsor
- Shenogen Pharma Group
- Start
- Sep 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Icaritin, sorafenib in hepatocellular carcinoma (HCC), sponsored by Shenogen Pharma Group. Started Sep 2017; status: active.
02
Drugs
Icaritinsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20170668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170668.